Max Schlaak

14.0k total citations · 1 hit paper
275 papers, 7.5k citations indexed

About

Max Schlaak is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Max Schlaak has authored 275 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 51 papers in Immunology. Recurrent topics in Max Schlaak's work include Allergic Rhinitis and Sensitization (41 papers), Food Allergy and Anaphylaxis Research (37 papers) and Cancer Immunotherapy and Biomarkers (30 papers). Max Schlaak is often cited by papers focused on Allergic Rhinitis and Sensitization (41 papers), Food Allergy and Anaphylaxis Research (37 papers) and Cancer Immunotherapy and Biomarkers (30 papers). Max Schlaak collaborates with scholars based in Germany, United States and Switzerland. Max Schlaak's co-authors include Joachim Müller‐Quernheim, P. Zabel, Wolf‐Meinhard Becker, Gernot Zissel, Alexander Shimabukuro‐Vornhagen, Hans Schlößer, Michael S. von Bergwelt‐Baildon, Matthias Kochanek, Boris Böll and Hans‐Joachim Stemmler and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Max Schlaak

259 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cytokine release syndrome

2018 1.2k citations Max Schlaak et al. Journal for ImmunoTherapy of Cancer profile →

Peers

Countries citing papers authored by Max Schlaak

Since Specialization

Citations

This map shows the geographic impact of Max Schlaak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Schlaak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Schlaak more than expected).

Fields of papers citing papers by Max Schlaak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Schlaak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Schlaak. The network helps show where Max Schlaak may publish in the future.

Co-authorship network of co-authors of Max Schlaak

This figure shows the co-authorship network connecting the top 25 collaborators of Max Schlaak. A scholar is included among the top collaborators of Max Schlaak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Schlaak. Max Schlaak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), L Arnold, (unknown), Friedegund Meier, (unknown), Katharina Meier, (unknown), Max Schlaak, Anja Gesierich, (unknown), Jörg Trojan, Johannes Kleemann, Bastian Schilling	0
2	Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma 2025 ·Clinical Cancer Research ·Ka‐Won Noh, (unknown), Doris Helbig, (unknown), (unknown), Max Schlaak, Tilo Biedermann, Reinhard Büttner, (unknown)	0
3	How to treat primary cutaneous B cell lymphoma – Results from a monocentric cohort study on 98 patients 2025 ·JDDG Journal der Deutschen Dermatologischen Gesellschaft ·(unknown), (unknown), Franz J. Hilke, Rose K. C. Moritz, Thomas Eigentler, Max Schlaak, Gábor Dobos	1
4	Real‐world management of patients with complete response under immune‐checkpoint inhibition for advanced melanoma 2025 ·JDDG Journal der Deutschen Dermatologischen Gesellschaft ·(unknown), Elisabeth Livingstone, Kai‐Martin Thoms, Markus V. Heppt, Frank Meiß, Anja Gesierich, Konstantin Drexler, Lucie Heinzerling, Friedegund Meier, Christian Menzer, Max Schlaak, Lisa Zimmer, Andrea Forschner	0
5	LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial 2023 ·Annals of Oncology ·Sophie Piperno‐Neumann, (unknown), Piotr Rutkowski, J.F. Baurain, Max Schlaak, Marcus O. Butler, Ryan J. Sullivan, Reinhard Dummer, (unknown), (unknown), (unknown), Sebastian Ochsenreither, Anthony M. Joshua, (unknown), Brendan D. Curti, (unknown), Omid Hamid, Linda Collins, Christopher P. Holland, Paul Nathan	0
6	Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma 2022 ·Cancers ·Dirk Tomsitz, Max Schlaak, (unknown), (unknown), (unknown), (unknown), (unknown), Lars E. French, Lucie Heinzerling	11
7	Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells 2014 ·Cancer Immunology Research ·Philipp Müller, Kea Martin, Sebastian Theurich, Jens Schreiner, Spasenija Savic, Grzegorz Terszowski, Didier Lardinois, Viola Heinzelmann‐Schwarz, Max Schlaak, Hans Michael Kvasnicka, Giulio C. Spagnoli, Stephan Dirnhofer, Daniel E. Speiser, Michael von Bergwelt‐Baildon, Alfred Zippelius	150
8	Mast cells play a protumorigenic role in primary cutaneous lymphoma 2012 ·Blood ·Anja Rabenhorst, Max Schlaak, Lukas C. Heukamp, Anja Förster, Sebastian Theurich, Michael von Bergwelt‐Baildon, Reinhard Büttner, Peter Kurschat, Cornelia Mauch, Axel Roers, Karin Hartmann	105
9	Results from a Genome-wide Search for Predisposing Genes in Sarcoidosis 2001 ·American Journal of Respiratory and Critical Care Medicine ·Manfred Schürmann, (unknown), Bertram Müller‐Myhsok, Max Schlaak, Joachim Müller‐Quernheim, E. Schwinger	141
10	Dietary lectins can inducein vitro release of IL-4 and IL-13 from human basophils 1999 ·European Journal of Immunology ·Helmut Haas, Franco H. Falcone, Gabriele Schramm, Karin Haisch, Bernhard F. Gibbs, (unknown), (unknown), Wolf‐Meinhard Becker, Hans‐Joachim Gabius, Max Schlaak	84
11	Dietary lectins can induce in vitro release of IL-4 and IL-13 from human basophils 1999 ·European Journal of Immunology ·Helmut Haas, Franco H. Falcone, Gabriele Schramm, Karin Haisch, Bernhard F. Gibbs, (unknown), (unknown), Wolf‐Meinhard Becker, Hans‐Joachim Gabius, Max Schlaak	9
12	Analysis of the Kveim-Siltzbach Test Reagent for Bacterial DNA 1999 ·American Journal of Respiratory and Critical Care Medicine ·Elvira Richter, Yash P. Kataria, Gernot Zissel, J Homolka, Max Schlaak, Joachim Müller‐Quernheim	17
13	Increased Expression of Proinflammatory Chemokines in Bronchoalveolar Lavage Cells of Patients with Progressing Idiopathic Pulmonary Fibrosis and Sarcoidosis 1998 ·Journal of Investigative Medicine ·Manfred W. Ziegenhagen, Silke Schrum, Gernot Zissel, Peter F. Zipfel, Max Schlaak, Joachim Müller‐Quernheim	112
14	Serum Level of Interleukin 8 Is Elevated in Idiopathic Pulmonary Fibrosis and Indicates Disease Activity 1998 ·American Journal of Respiratory and Critical Care Medicine ·Manfred W. Ziegenhagen, P. Zabel, Gernot Zissel, Max Schlaak, Joachim Müller‐Quernheim	112
15	Allergenic Activity of a Major Grass Pollen Allergen Is Elevated in the Presence of Nasal Secretion 1998 ·American Journal of Respiratory and Critical Care Medicine ·Albrecht Bufe, Kirsten Gehlhar, Gabriele Schramm, Max Schlaak, Wolf‐Meinhard Becker	27
16	Sarcoidosis: TNF- α Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers 1997 ·American Journal of Respiratory and Critical Care Medicine ·Manfred W. Ziegenhagen, (unknown), Gernot Zissel, P. Zabel, Max Schlaak, Joachim Müller‐Quernheim	187
17	TCR V β Families in T Cell Clones from Sarcoid Lung Parenchyma, BAL, and Blood 1997 ·American Journal of Respiratory and Critical Care Medicine ·Gernot Zissel, (unknown), Bernhard Fleischer, Max Schlaak, Joachim Müller‐Quernheim	18
18	Anti-Inflammatory Cytokine Release by Alveolar Macrophages in Pulmonary Sarcoidosis 1996 ·American Journal of Respiratory and Critical Care Medicine ·Gernot Zissel, J Homolka, JF Schlaak, Max Schlaak, Joachim Müller‐Quernheim	83
19	Successful Technique for the Selective Production of Monoclonal Antibodies Against a Major Allergenic Component in Timothy Pollen Extract 1993 ·Hybridoma ·(unknown), Wolf‐Meinhard Becker, Max Schlaak	3
20	[Length of survival of donor lymphocytes in the peripheral blood of recipients following fresh blood transfusion]. 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·(unknown), (unknown), (unknown), Max Schlaak	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact